Sumitomo Pharma America, Inc.
↗Marlborough, USA
Sumitomo Pharma America (SMPA) is a science-based, technology-driven biopharmaceutical company formed in July 2023 through the consolidation of seven U.S. subsidiaries of Sumitomo Pharma Co., Ltd., including Sunovion, Myovant, Urovant, and Sumitomo Pharma Oncology. The company operates as a key growth engine for its Japanese parent company, focusing on high-unmet-need areas such as psychiatry, neurology, oncology, urology, women's health, and rare diseases.
SMPA leverages advanced computational technology and proprietary AI platforms like 'DrugOME' to accelerate drug discovery and development. The company manages a diverse portfolio of six marketed products and a robust pipeline of early- to late-stage assets, with a strategic emphasis on regenerative medicine and cell therapy through its 'Reboot 2027' initiative.
CLASSIFICATION
Company Type:Pharma
Therapeutic Areas:
Industry:Pharmaceuticals
Sub-Industry:Oncology, CNS, and Regenerative Medicine
SIZE & FINANCIALS
Employees:1001-5000
Revenue:$2B-$3B
Founded:2023
Ownership:subsidiary
Status:operating
FUNDING
Stage:Pre-IPO
Investors:Sumitomo Pharma Co., Ltd.
STOCK
Exchange:TSE
Ticker:4506
Market Cap:$3.7B
PIPELINE
Stage:Commercial
Lead Drug Stage:Phase 3 / Commercial
Modalities:Small molecule, iPS cell-derived therapy, Regenerative medicine, Advanced computational analytics
Active Trials:45
Trial Phases:Phase 1: 15 | Phase 2: 18 | Phase 3: 12 | Phase 4: 5
FDA Approvals:6
EMA Approvals:4
CORPORATE STRUCTURE
Parent Company:Sumitomo Pharma Co., Ltd.
Subsidiaries:Sumitomo Pharma Canada, Inc., Spirovant Sciences, Inc.
Key Partnerships:National Cancer Institute (Enzomenib collaboration), Exscientia (AI drug discovery), Knight Therapeutics (Canadian commercialization), RACTHERA (Joint venture with Sumitomo Chemical)
COMPETITION
Position:Leader
Competitors:Takeda Pharmaceutical, Astellas Pharma, Pfizer, AbbVie, Roche
LEADERSHIP
Key Executives:
Tsutomu Nakagawa, Ph.D. - President and CEO
Yumi Sato - Chief Development Officer
Jatin Shah, M.D. - Chief Medical Officer, Oncology
Board Members:Toru Kimura, Tsutomu Nakagawa, Motoyuki Sakai
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Sumitomo Pharma America, Inc.. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.